ライフサイエンスコーパス: bloating

1 stency, straining, abdominal discomfort, and bloating.

2 comfort for at least 2 days/wk) and reported bloating.

3 , relating these changes to the sensation of bloating.

4 llenging symptoms of pain, constipation, and bloating.

5 mptoms of abdominal fullness, distension, or bloating.

6 terval (CI): -2.66 to -1.83; P < 0.001], gas bloating [11% vs 18%; relative risk (RR) 0.59; 95% CI: 0

7 ed abdominal size; 3.6 (95% CI, 1.8-7.0) for bloating; 2.5 (95% CI, 1.3-4.8) for urinary urgency; and

8 e other gastrointestinal manifestations were bloating (20%), aphthous stomatitis (18%), alternating b

9 common were back pain (45%), fatigue (34%), bloating (27%), constipation (24%), abdominal pain (22%)

10 imum pain, 2.1 +/- 0.4; nausea, 2.2 +/- 0.4; bloating, 3.7 +/- 0.2).

11 with mastocytosis than in healthy subjects: bloating (33% vs 7.2%, P < .0001), abdominal pain (27.3%

12 40-0.99; P = 0.05), and inability to relieve bloating (34% vs 44%; RR: 0.74; 95% CI: 0.55-0.99; P = 0

13 in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% v

14 antly less reduced and the prevalence of gas bloating (7.1% vs. 21.4%; P = 0.242) and increased flatu

15 he most common symptoms were diarrhea (86%), bloating (77.5%), and abdominal pain (71.3%).

16 ms associated with lymphangioleiomyomas were bloating, abdominal pain, and edema of the lower extremi

17 provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.

18 obal IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during t

19 s assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency.

20 the period of high lactose intake; however, bloating, abdominal pain, diarrhea, and the global perce

21 luding early satiety, postprandial fullness, bloating, abdominal swelling, nausea, vomiting, and retc

22 ymptom of abdominal pain in conjunction with bloating and bowel movement disorder.

23 More severe symptoms (bloating and constipation) were characteristic of patien

24 iagnosis of IBS; in particular, inclusion of bloating and de-emphasis of pain as criteria were consid

25 visits for abdominal pain, constipation, and bloating and diagnoses of IBS; and IMS Health's National

26 observations in IBS, including postprandial bloating and distension, altered motility, visceral hype

27 Bloating and distention may differ pathophysiologically

28 utcomes comprised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool c

29 re air venting from the stomach and less gas bloating and flatulence, whereas reflux is reduced to a

30 Overweight patients had more bloating and gastric retention at 2 hours but less sever

31 e symptoms including inability to belch, gas bloating and increased flatulence.

32 aily activities, recording their symptoms of bloating and pain together with bowel habit.

33 In contrast, scores of postprandial bloating and pain were higher with increased body mass i

34 ealthcare seeking were presence of abdominal bloating and vomiting (p < 0.05).

35 Abdominal pain, bloating and weight loss were the commonest symptoms ass

36 ssion of increased rectal gas, and abdominal bloating), and five were examined for breath hydrogen ex

37 ndrome with constipation, 15 with functional bloating, and 3 with irritable bowel syndrome with alter

38 he developed symptoms of diarrhea, abdominal bloating, and discomfort in the midepigastrium.

39 vomiting, as well as nausea, abdominal pain, bloating, and early satiety compared with placebo (compo

40 abdominal symptoms, including discomfort and bloating, and global measures of IBS-C compared with pla

41 along with scores for postprandial fullness, bloating, and nausea (all P < .05).

42 pairment of intestinal propulsion, abdominal bloating, and pain.

43 it only occurs in half of patients reporting bloating, and the 2 only correlate in IBS-constipation.

44 %) experiencing nausea, diarrhoea, abdominal bloating, and weight loss greater than 2 kg (mean of 4 k

45 pt less heartburn at 3 and 6 months and less bloating at 12 months with nonabsorbable mesh; more hear

46 ic complaints, such as breast tenderness and bloating, can also be problematic.

47 Whereas the majority of FGID, including IBS, bloating, constipation, chronic functional abdominal pai

48 including globus, rumination syndrome, IBS, bloating, constipation, functional abdominal pain, sphin

49 Bloating correlated strongly only with distention in IBS

50 no-switch group, but rates of diarrhoea and bloating decreased compared with baseline from week 4 to

51 visits for abdominal pain, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); a

52 rted 7 multi-item scales: reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotion

53 ion [grade 3]; recurrence of abdominal pain, bloating, diarrhoea, and urinary tract infection [grade

54 Breast tenderness and bloating did not result from sodium retention in the lut

55 ctional diarrhea (FDr); functional abdominal bloating/distention (FAB/D); and unspecified FBD (U-FBD)

56 end points included nausea, abdominal pain, bloating, early satiety, as well as the composite score

57 year-old male presented with upper abdominal bloating followed by modest hematemesis that led to the

58 specific FGIDs of IBS, functional abdominal bloating, functional constipation and pelvic floor dyssy

59 Irritable bowel syndrome (IBS), functional bloating, functional constipation, and functional diarrh

60 Its symptoms include chronic abdominal pain, bloating gas, diarrhea and constipation.

61 age articles beginning with those related to bloating, gas, and IBS.

62 g (1.06 [1.50] vs 0.53 [0.90]; P = .73), and bloating/gas (3.28 [1.71] vs 2.23 [1.72]; P = .05) at th

63 onsistency, straining, abdominal discomfort, bloating, global assessments, and quality of life.

64 inal bacterial overgrowth (SIBO) may explain bloating in IBS is supported by greater total hydrogen e

65 n is used most frequently, but postoperative bloating, inability to belch, and dysphagia occur.

66 l phase (P < 0.001) and those of swelling or bloating increased twofold to threefold during early men

67 The combination of bloating, increased abdominal size, and urinary symptoms

68 5 gastrointestinal symptoms (abdominal pain, bloating, nausea, gas, and fullness) before breakfast an

69 Neither bloating nor distention in IBS was related to body mass

70 ed distension of the outer unit membrane and bloating of the internal mitochondrial compartment.

71 The relationship between the sensation of bloating, often ranked as the most bothersome symptom by

72 , abdominal pain, postprandial fullness, and bloating) on a 0-10 scale.

73 bility, sadness, anxiety, food cravings, and bloating) on dutasteride compared with placebo.

74 t symptom (constipation, diarrhoea, pain, or bloating) or combination of symptoms is the next step.

75 absorption of partially digested food causes bloating, overfilled intestines, abdominal pain, excessi

76 ain effect of anxiety levels on fullness and bloating (P < .04), and of depression levels on abdomina

77 al pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p <

78 somatization-by-time interaction effects for bloating (P = .005), and nausea (P = .02), and a nonsign

79 d the number of days with moderate to severe bloating (p = 0.03) and the proportion of patients with

80 (P-treatment x time interaction < 0.05), and bloating (P-treatment x time interaction < 0.001) compar

81 Bloating, pain, and passage of wind also were reduced wh

82 e 92% of these patients share the symptom of bloating regardless of their predominant complaint.

83 inability to belch, and inability to relieve bloating remained lower after 180-degree LAF.

84 consuming gluten (P = .049), as was the GSRS bloating score (P = .003).

85 n addition, rifaximin recipients had a lower bloating score after treatment.

86 d adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loose stool, located a

87 controls; increases correlated with pain and bloating scores.

88 ns with pain, burning sensation, nausea, and bloating scores.

89 d, with strong correlations existing between bloating/shrinkage during sintering, density and water a

90 bowel habit, reported significantly greater bloating than controls (P < .0001).

91 ) causing symptoms ranging from postprandial bloating to recurrent vomiting.

92 Symptoms of bloating usually indicate the irritable bowel syndrome,

93 Mean scores for GSRS-IBS bloating were 9.3 +/- 3.5, 11.6 +/- 3.5, and 10.1 +/- 3.

94 Pain, nausea, and bloating were rated during baseline and distentions (0-5

95 ients who had adequate relief of IBS-related bloating, were assessed weekly.

96 es excessive gas production) and feelings of bloating (which are usually unrelated to excessive gas p

97 (P < 0.05) increase in feelings of abdominal bloating (which the participants perceived as excessive

98 Most patients had abdominal pain and bloating, which resolved with the diet.